GB-4362
Various (to reduce MMAE ADC toxicity)
PreclinicalIND 'study may proceed' granted Dec 2025
Key Facts
Indication
Various (to reduce MMAE ADC toxicity)
Phase
Preclinical
Status
IND 'study may proceed' granted Dec 2025
Company
About Generate Biomedicines
Generate Biomedicines is at the forefront of integrating machine learning, biological engineering, and medicine to create a new paradigm in drug discovery called Generative Biology™. Its proprietary platform learns from millions of proteins to generate novel therapeutics with specific functions, drastically accelerating R&D. The company has advanced a Phase 3 anti-TSLP antibody for severe asthma, built a diverse preclinical pipeline in oncology and immunology, and secured strategic collaborations, positioning it as a leader in AI-driven biotherapeutics.
View full company profile